98%
921
2 minutes
20
Objective: To investigate the influence of systemic application of Alendronate sodium, a bone resorption inhibitor, on the osseointegration of implant-bone interface in estrogen-deficient rabbits through mechanical assessment.
Methods: 27 five-month-old Japanese white female rabbits were randomly divided into three groups (9 rabbits each group). An ovariectomy group (OVX), an ovariectomy and Alendronate sodium group (ALN) and a shamed-operated group (S). 12 weeks after operation, implants were installed into bilateral distal femurs and proximal tibias in each group. Alendronate sodium was administrated by intraperitoneal injection in ALN group; meanwhile equivalent of normal saline was administrated by intraperitoneal injection in OVX group and S group. Bone mineral density was measured right after the implant operation and also in 4, 8, 12 weeks. Torque-out values were measured in 4, 8, 12 weeks after animal sacrifice.
Results: Bone mineral density of tibias in ALN group was closed to S group and was significantly different from OVX group (P < 0.05) after 8 weeks. While after 12 weeks, the bone mineral density of tibias and femurs in ALN group was both closed to S group and was significantly different from OVX group (P < 0.05). The torque-out values of tibias in ALN group were closed to S group and were significantly different from OVX group (P < 0.05) after 8 weeks. After 12 weeks, the torque-out values of tibias and femurs in ALN group were both closed to S group and were significantly different from OVX group (P < 0.05).
Conclusion: Systemic application of Alendronate sodium in osteoporosis rabbits can improve the bone-implant osseointegration significantly.
Download full-text PDF |
Source |
---|
Eye (Lond)
September 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada.
Background: Blepharitis, meibomian gland dysfunction (MGD), and chalazia are common disorders impacting quality of life. This population-based, pharmacovigilance study aims to identify systemic drugs disproportionately linked to these disorders.
Methods: Data from the Food and Drug Administration Adverse Event Reporting System (FAERS) were analysed (Q4 2003 to Q2 2024).
Calcif Tissue Int
September 2025
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research (PGIMER), 001, Nehru Extension Block, Chandigarh, India.
Rare diseases, defined by the 2002 Rare Disease Act, affect fewer than 5 in 10,000 individuals. Rare metabolic bone diseases (MBDs), such as osteogenesis imperfecta, hypophosphatasia, osteopetrosis, and other unclassified disorders, can disrupt bone development and remodeling, posing diagnostic and management challenges. This study analyzed data from the rarembd.
View Article and Find Full Text PDFInt J Biol Macromol
September 2025
Marine College, Shandong University, Weihai 264209, China. Electronic address:
The current method of using scaffold materials to repair bone defects still faces limitations in achieving biomimetic mineralization and endogenous bone tissue regeneration. Therefore, we have developed a novel ALN doped chitosan/hydroxyapatite (CS/ALN/nHAP) micro nano hybrid scaffold based on in situ tissue engineering principles. The addition of alendronate (ALN) increases nucleation sites, enhances biomimetic mineralization of nHAP in situ, and promotes the aggregation of endogenous stem cells.
View Article and Find Full Text PDFSci Prog
September 2025
The Third Ward of Orthopaedic Department, General Hospital of Ningxia Medical University, Yinchuan, PR China.
ObjectivesThis systematic review and meta-analysis aims to evaluate whether alendronate therapy improves survival rates in patients with osteoporosis, in addition to its known benefits in reducing fracture risk.MethodsA comprehensive literature search was conducted across Embase, Web of Science, Medline, Cochrane Library, and ClinicalTrials.gov to identify randomized, placebo-controlled clinical trials involving alendronate therapy in osteoporosis patients.
View Article and Find Full Text PDFAdv Healthc Mater
September 2025
College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China.
To balance the requirement of high mechanical properties and convenient injectability for the hydrogel design of osteoporotic bone defects (OBD) repair, a hierarchical hydrogel stiffening strategy is proposed through the synergetic utilizing of rapidly formed dynamic hydrazone crosslinking, high-strength double-bond chemical crosslinking, and contraction of activated shape-memory short fibers (SMSFs). In detail, the Schiff Base reaction mediated first network enabled stable precursor retention at the injection site without compromising injectability. Subsequent radical polymerization by photocrosslinking enhanced the hydrogel stiffness from 9.
View Article and Find Full Text PDF